Evoke PharmaEVOK
13F holders, Q2 2024 (June 30)16holders +1
4new positions
3sold out
1famous investor
$0.53avg. 13F price*
At the end of Q2 2024, 16 institutions reported holding Evoke Pharma Inc. (EVOK) in their 13F filings, up 1 from Q1 2024. 4 opened new positions and 3 sold out. The largest holders were AIGH Capital Management LLC ($448K), Bleichroeder LP ($436K) and Altium Capital Management LLC ($366K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Evoke Pharma Inc.
- CUSIP
- 30049G203
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $12K |
| Exits | 3 | $15K |
All 13F filers, Q1 2024 → Q2 2024: 45,411 shares bought and 56,908 shares sold, net −11,497 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| AIGH Capital Management LLC | 0.22% | No change | 846,564 | $448K |
| Bleichroeder LP | 0.13% | No change | 825,000 | $436K |
| Altium Capital Management LLC | 0.15% | Reduce -4.5% | 692,440 | $366K |
| Nantahala Capital Management, LLC | 0.04% | No change | 675,000 | $357K |
| Geode Capital Management, LLC | 0.00% | Add +83.6% | 49,691 | $26K |
| Vanguard Group Inc. | 0.00% | No change | 29,851 | $16K |
| Citadel Advisors | 0.00% | New | 11,911 | $6K |
| State Street Corp. | 0.00% | New | 10,660 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +1.0% | 7,479 | $4K |
| BlackRock Inc. | 0.00% | No change | 1,464 | $774 |
| UBS Group AG | 0.00% | No change | 1,107 | $586 |
| Morgan Stanley | 0.00% | No change | 375 | $198 |
| NewEdge Advisors, LLC | 0.00% | No change | 208 | $110 |
| FMR LLC | 0.00% | New | 71 | $38 |
| Bank of America Corp. | 0.00% | New | 69 | $37 |
| Royal Bank of Canada | 0.00% | No change | 28 | $0 |
"% of holder's portfolio" is EVOK's weight in each manager's 13F, not the share of Evoke Pharma Inc. the manager owns.